EN DE
STOCK COMPARISON

Sonova H vs Abbott Laboratories: Fair Value & Quality

Both stocks run through our valuation models. Here is how Sonova H (SOON) and Abbott Laboratories (ABT) compare, as of Aug 14, 2026.

As of Aug 14, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Sonova H trades at CHF 241 versus a fair value of CHF 159 (-34%), while Abbott Laboratories trades at $111 versus $74.79 (-33%).
Sonova H
SOON.SW · CHF · Health Care
-34%
upside to fair value
overvalued
PriceCHF 241
Fair ValueCHF 159
Quality71/100
Abbott Laboratories
ABT · USD · Health Care
-33%
upside to fair value
overvalued
Price$111
Fair Value$74.79
Quality67/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Sonova HAbbott Laboratories
Valuation
26.7×P/E (TTM)27.7×
4.20×P/S (TTM)3.89×
5.80×P/B3.36×
18.8×EV/EBITDA15.1×
1.24×PEG1.47×
2.3%Dividend yield
CHF 4.70Dividend per share
Profitability
12%Net margin14%
20%Operating margin13%
21%Return on equity12%
8%Return on assets6%
Growth
-1%Revenue growth (YoY)8%
-1.2%Avg. growth/yr (3Y)0.5%
6.7%Avg. growth/yr (5Y)5.1%
Balance & size
0.52×Debt / equity0.19×
$15BMarket cap$175B
mixedGrowth qualityhealthy

Abbott Laboratories leads: 6 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Sonova Hof which business quality 70 · market factors 63 Abbott Laboratoriesof which business quality 66 · market factors 53
ProfitabilityMargins and returns on capital today
60
50
Quality GrowthAre margins and returns improving?
49
47
CashflowEarnings quality: real cash, not paper profit
76
71
Fin. StrengthBalance sheet, leverage, solvency risk
76
80
InvestmentDisciplined investing over empire-building
89
65
Low VolatilityCalm price path (market factor)
63
83
MomentumPrice trend over the last 3–12 months (market factor)
59
43
52W MomentumDistance to the 52-week high (market factor)
72
38
Net IssuanceBuybacks instead of dilution
75
84

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Sonova H

DCF ModelsCHF 166
Earnings-BasedCHF 72.69
Dividend DiscountCHF 75.64
MultiplesCHF 148
Asset-BasedCHF 29.48
Growth DCFCHF 159
Economic ProfitCHF 87.43
Growth EarningsCHF 141

26 of 26 models see the stock below the current price.

Abbott Laboratories

DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Sonova H
Bear CHF 98.43Fair Value CHF 159Bull CHF 199
CHF 241 = current price (white tick)
Abbott Laboratories
Bear $51.13Fair Value $74.79Bull $94.43
$111 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Sonova H · Health Care

Quality score71 · Top 25%
Fair value upside-34% · below median

Abbott Laboratories · Health Care

Quality score67 · Top 25%
Fair value upside-33% · below median

Bottom line

As of Aug 14, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Sonova H trades at CHF 241 versus a fair value of CHF 159 (-34%), while Abbott Laboratories trades at $111 versus $74.79 (-33%).

Sonova H has the higher quality score (71/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.